Analysts Offer Insights on Healthcare Companies: Audentes Therapeutics (NASDAQ: BOLD) and Constellation Pharmaceuticals Inc (NASDAQ: CNST)

By Ryan Adsit

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Audentes Therapeutics (BOLDResearch Report) and Constellation Pharmaceuticals Inc (CNSTResearch Report) with bullish sentiments.

Audentes Therapeutics (BOLD)

In a report released today, Debjit Chattopadhyay from H.C. Wainwright maintained a Buy rating on Audentes Therapeutics, with a price target of $44. The company’s shares closed on Friday at $38.19.

Chattopadhyay observed:

“Our $44 (raised from $33) price target on shares of Audentes is based on a 12-year DCF-based, sum-of-the-parts analysis, which includes AT132 being developed for XLMTM and AT845, that is being advanced as a one-and-done approach for Pompe disease. Note, our prior $33 target, did not reflect AT-845. Our DCF is driven by a: beta of 1.25, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 9.0%, and tax rate of 15% beginning in FY 2028.”

According to TipRanks.com, Chattopadhyay is a 3-star analyst with an average return of 2.5% and a 48.3% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Voyager Therapeutics Inc, and Mersana Therapeutics Inc.

Audentes Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $39.60.

See today’s analyst top recommended stocks >>

Constellation Pharmaceuticals Inc (CNST)

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Constellation Pharmaceuticals Inc, with a price target of $18. The company’s shares closed on Friday at $10.

Fein observed:

“Valuation and risks to achievement of target price. Our price target of $18/share is based on an equally-weighted composite of: (a) $22.4/share, as a 25x multiple of taxed and diluted $6.68 discounted back to FY19 at 25% (in line with the expected P/E multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $13.4/ share (discounted cash flow analysis using a 20% discount rate and 2% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company).”

According to TipRanks.com, Fein is a 5-star analyst with an average return of 9.2% and a 48.3% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, ACADIA Pharmaceuticals Inc, and Strongbridge Biopharma Plc.

Constellation Pharmaceuticals Inc has an analyst consensus of Strong Buy, with a price target consensus of $16.33, which is a 63.3% upside from current levels. In a report issued on March 15, Oppenheimer also reiterated a Buy rating on the stock with a $14 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.